Published in Blood Transfus on January 01, 2008
Hepatitis E: an old infection with new implications. Blood Transfus (2014) 0.80
Plasma, guidelines, and evidence-based medicine. Blood Transfus (2008) 0.78
Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document. Blood Transfus (2016) 0.75
Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol (2004) 3.52
Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology (1996) 3.46
Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion (2007) 3.38
Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood (2002) 3.18
The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood (1987) 2.84
Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol (2003) 2.77
Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev (2006) 2.48
Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion (2006) 2.45
Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg (2002) 2.41
THE PLASMA CONCENTRATION OF FACTOR VIII IN THE NORMAL POPULATION. II. THE EFFECTS OF AGE, SEX AND BLOOD GROUP. Br J Haematol (1964) 2.41
Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang (2003) 2.33
Current status of solvent/detergent-treated frozen plasma. Transfusion (1998) 2.24
The two-event model of transfusion-related acute lung injury. Crit Care Med (2006) 2.23
The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia (2004) 1.92
Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev (2005) 1.91
Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang (2002) 1.80
Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med (2003) 1.79
Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA (1994) 1.67
Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet (1985) 1.66
Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma. Acta Paediatr (2002) 1.64
Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion (1999) 1.63
Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev (2006) 1.62
Influence of ABO blood groups on primary hemostasis. Transfusion (2001) 1.59
Measures to prevent TRALI. Vox Sang (2007) 1.58
Coagulant stability and sterility of thawed S/D-treated plasma. Transfusion (2002) 1.53
The how and why of exocytic vesicles. Transfusion (2006) 1.51
Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med (2006) 1.49
Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. Crit Care Med (2006) 1.49
A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion (2000) 1.48
Viral safety of solvent/detergent-treated plasma. Transfusion (2000) 1.46
Vitamin K-dependent coagulation factors and fibrinogen levels in FFP remain stable upon repeated freezing and thawing. Transfusion (2003) 1.45
Experimental animal model of refractoriness to donor platelets: the effect of plasma removal and the extent of white cell reduction on allogeneic alloimmunization. Transfusion (1993) 1.38
Transfusion-related acute lung injury. Transfus Med Rev (2003) 1.37
The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med (2001) 1.34
Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol (2002) 1.27
Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol (2000) 1.27
Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood (1992) 1.22
Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy. Transfusion (2005) 1.21
Transfusion-related acute lung injury (TRALI): clinical presentation, treatment, and prognosis. Crit Care Med (2006) 1.20
Transfusion-related acute lung injury (TRALI)--under-diagnosed and under-reported. Br J Anaesth (2003) 1.15
Thrombotic microangiopathies: an update. Hematology (2006) 1.15
Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion (1985) 1.14
ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang (1995) 1.11
Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol (2001) 1.10
Risks of fresh frozen plasma and platelets. J Trauma (2006) 1.07
Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood (1986) 1.06
Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol (2004) 1.06
Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol (2003) 1.02
Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res (2002) 1.01
Donor risk factors for white blood cell antibodies associated with transfusion-associated acute lung injury: REDS-II leukocyte antibody prevalence study (LAPS). Transfusion (2007) 1.01
Labile coagulation factors in thawed fresh frozen plasma prepared by two methods. Vox Sang (1984) 1.00
Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Res (2005) 0.99
Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci (2006) 0.99
The challenge of an increasingly expensive blood system. CMAJ (2003) 0.97
Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 0.96
Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia (2003) 0.96
Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion (2000) 0.95
Major blood group antigens--a determinant of factor VIII levels in blood? Thromb Haemost (1984) 0.95
Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev (2005) 0.94
Virus safety of human blood, plasma, and derived products. Thromb Res (2002) 0.94
Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol (1996) 0.94
Mechanisms of transfusion-related acute lung injury (TRALI): anti-leukocyte antibodies. Crit Care Med (2006) 0.93
Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci (2006) 0.92
Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis (2003) 0.92
Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med (2004) 0.91
In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang (1998) 0.91
Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion (2003) 0.90
Factor VIII levels and blood group antigens. Thromb Haemost (1983) 0.90
Thrombotic thrombocytopenic purpura--then and now. Semin Thromb Hemost (2006) 0.90
Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol (2004) 0.90
Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion (2001) 0.89
Pathogen inactivation technology: cleansing the blood supply. J Intern Med (2005) 0.89
Transfusion-related acute lung injury. Curr Opin Hematol (2005) 0.88
Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev (2005) 0.88
Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes. Thromb Res (2002) 0.87
Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood (1999) 0.86
Effects of extended storage of whole blood before leucocyte depletion on coagulation factors in plasma. Vox Sang (2004) 0.86
Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. J Heart Lung Transplant (1999) 0.86
The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood. Transfusion (2005) 0.86
Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro. Thromb Haemost (2003) 0.86
The relationship between ABO groups and subgroups, factor VIII and von Willebrand factor. Haematologica (2007) 0.85
Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion (2007) 0.85
Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica (2006) 0.85
Transfusion-related acute lung injury and leucocyte-reacting antibodies. Vox Sang (2007) 0.85
Factors determining quality of plasma. Vox Sang (1998) 0.85
Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Eur J Immunogenet (2004) 0.85
SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang (1998) 0.85
The impact of the intensity of serial automated plasmapheresis and the speed of deep-freezing on the quality of plasma. Transfusion (2001) 0.85
Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol (2004) 0.84
Leucocyte-derived bioactive substances in fresh frozen plasma. Br J Anaesth (1997) 0.84
Cumulative risks of early fresh frozen plasma, cryoprecipitate and platelet transfusion in Europe. J Trauma (2006) 0.84
Blood donor and component management strategies to prevent transfusion-related acute lung injury (TRALI). Crit Care Med (2006) 0.84
Practical guidelines for the clinical use of plasma. Thromb Res (2002) 0.83
Pathogen inactivated transfusion plasma: existing and emerging methods. Vox Sang (2002) 0.83
Quality assessment of seven types of fresh-frozen plasma leucoreduced by specific plasma filtration. Vox Sang (2003) 0.83
Solvent-detergent-treated fresh frozen plasma: a superior alternative to standard fresh frozen plasma? J Cardiothorac Vasc Anesth (2000) 0.83
Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang (1998) 0.83
Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox Sang (2007) 0.83
Improvement of plasma quality as raw material for factor VIII:C concentrates. Storage of whole blood and plasma and interindividual plasma levels of fibrinopeptide A. Vox Sang (1983) 0.83
White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion (2005) 0.82
The Chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus (2008) 1.53
Red blood cell storage: the story so far. Blood Transfus (2010) 1.46
Blood-related proteomics. J Proteomics (2009) 1.22
Peroxiredoxin-2 as a candidate biomarker to test oxidative stress levels of stored red blood cells under blood bank conditions. Transfusion (2011) 1.14
The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation. Blood Transfus (2010) 1.03
Reduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood components. Blood Transfus (2009) 0.96
How has proteomics informed transfusion biology so far? Crit Rev Oncol Hematol (2010) 0.89
Tuscan study on the appropriateness of fresh-frozen plasma transfusion (TuSAPlaT). Blood Transfus (2007) 0.87
Transfusion medicine in the era of proteomics. J Proteomics (2008) 0.87
Interlaboratory study to evaluate the performance of laboratories involved in West Nile virus RNA screening of blood and blood components by nucleic acid amplification testing in Italy. Blood Transfus (2011) 0.87
Blood proteomics and transfusion safety. J Proteomics (2009) 0.86
Red blood cell storage lesion and adverse clinical outcomes: post hoc ergo propter hoc? Blood Transfus (2012) 0.86
Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation. Electrophoresis (2010) 0.82
Detection of West Nile virus RNA (lineages 1 and 2) in an external quality assessment programme for laboratories screening blood and blood components for West Nile virus by nucleic acid amplification testing. Blood Transfus (2012) 0.81
Alternative blood products and clinical needs in transfusion medicine. Stem Cells Int (2012) 0.81
Integrated human surveillance systems of West Nile virus infections in Italy: the 2012 experience. Int J Environ Res Public Health (2013) 0.80
Umbilical cord blood stem cells: towards a proteomic approach. J Proteomics (2009) 0.80
In silico analyses of proteomic data suggest a role for heat shock proteins in umbilical cord blood hematopoietic stem cells. Stem Cell Rev (2010) 0.80
Cord blood stem cell banking: a snapshot of the Italian situation. Transfusion (2011) 0.78
Collection, storage, and allogeneic use of cord blood: informed consent form used by the italian biobank network. Biopreserv Biobank (2011) 0.78
Changing blood donor screening criteria from permanent deferral for men who have sex with men to individual sexual risk assessment: no evidence of a significant impact on the human immunodeficiency virus epidemic in Italy. Blood Transfus (2013) 0.78
Ex vivo generated red cells as transfusion products. Stem Cells Int (2012) 0.76
Institutional authorisation and accreditation of Transfusion Services and Blood Donation Sites: results of a national survey. Blood Transfus (2011) 0.75
Transfusion medicine and proteomics: an alliance for blood quality and safety. Blood Transfus (2010) 0.75
Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry. Blood Transfus (2010) 0.75
Lymphocytapheresis in the treatment of psoriasis vulgaris. J Clin Apher (2006) 0.75
A case report of long-term remission of ulcerative colitis after lymphocyto-plasmapheresis. Ther Apher Dial (2007) 0.75